🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "major milestone" in the fight against drug-resistant strains of the pathogen, according to health experts.

A Global Health Concern

Gonorrhoea infections are increasing worldwide, with estimates suggesting over 82 million new cases per year. Especially elevated rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely advancement in the context of increasing worldwide cases, escalating drug resistance and the very limited available drugs currently available.”

Health officials are deeply concerned about the surge in treatment-resistant strains. The WHO has designated it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Receive Clearance

Zoliflodacin, also known as Nuzolvence, was cleared by the US FDA in December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers believe that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the drugmaker GSK, also received approval in close succession. This drug, which is employed against urinary tract infections, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment emerged from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to see it through.

“This authorization represents a huge turning point in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Clinical Trial Data and Global Access

According to results detailed in a prominent scientific publication, zoliflodacin eradicated over nine in ten of cases of the STI. This establishes an similar efficacy with the existing first-line therapy, which involves an injection and a pill. The study enrolled nearly 1,000 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the ability to register and commercialise the drug in numerous developing nations.

Medical professionals treating patients have expressed hope. Access to a single-dose, oral treatment such as this is seen as a "revolutionary step" for managing the epidemic. This is viewed as vital to alleviate the strain of the infection for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.